Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

Purpose: To prospectively study the pharmacokinetics and toxicity profile of docetaxel in elderly patients with cancer.

Patients And Methods: Docetaxel was administered at a dose 75 mg/m(2) once every 3 weeks to 25 elderly cancer patients aged >/= 65 years and 26 cancer patients aged younger than 65 years. Pharmacokinetic studies and toxicity assessments were performed during the first cycle of therapy.